Across Barriers GmbH was established in order to provide new technologies and services to those working in pharmaceutical, cosmetic and chemical research and development. At the core of Across Barriers' activities are in vitro models of cell and tissue systems which are used to simulate the transport of chemicals and drugs across biological barriers. Using these models Across Barriers can rapidly provide drug permeability information, giving its customers the following unique competitive advantages:

    Rapid large-scale screening of drug candidates allows promising substances to be identified at an early stage of the drug development process.

    The time and costs involved in developing active agents are significantly reduced. Cost-intensive and ethically controversial animal experiments can be reduced to a minimum. The in vitro models enable the classification of drug substances that are administered by novel dosage forms, such as inhalation aerosols or transdermal methods. They also provide mechanistic information on the behavior of substances in vivo. In collaboration with our analytical and physicochemical characterization division, we provide the full range of drug profiling methods required by the FDA's BCS guidelines, and thus offer our customers the possibility of being granted exemption from in vivo bioequivalence and bioavailability studies. The use of tissue and cell cultures in preclinical research represents an intelligent and innovative step in making the development of modern drugs and drug products faster, safer and more cost-effective. Across Barriers develops and markets validated cell and tissue models that ensure its customers have the competitive edge in one of today's leading technologies.